Roche brings breakthrough diagnostic technologies to support the region’s healthcare transformation

Q1. The Middle East has been described as entering a ‘new normal,’ where geopolitical and operational disruption is more frequent rather than less. How does that shape the way Roche Diagnostics is investing in the region?

At Roche Middle East, navigating complex or changing environments is nothing new to us. We are a highly resilient and passionate organization, and our focus always remains exactly where it belongs: on our purpose. We are driven by a commitment to make advanced healthcare innovation accessible to patients and healthcare systems, regardless of the circumstances.

Over the years, we have built a solid and flexible supply chain. This robust infrastructure is precisely what makes us a trusted and reliable partner for healthcare providers across the region, ensuring that critical diagnostic tools, which guide the vast majority of clinical decisions, are always available when they are needed most.

Our commitment to the Middle East remains entirely unchanged. We continue to invest heavily in the region by bringing our latest breakthrough technologies directly to local markets. A prime example of this is the rollout of our next-generation core lab technology, the cobas Mass Spec, in Saudi Arabia and the UAE. By delivering this level of cutting-edge innovation and fostering local expertise, we are proudly supporting Middle Eastern healthcare systems in building long-term capacity and sustainable resilience.

Q2. The cobas Mass Spec installation at King Faisal Specialist Hospital was the first outside the European Union. What does that decision say about Roche’s view of the Middle East?

This decision highlights how closely aligned we are with our global organization regarding the attractiveness of the Middle East as a premier environment to test, validate, and foster medical innovation. The region is moving incredibly fast, and it has become a dynamic hub for adopting advanced healthcare solutions.

In that context, we are incredibly proud to bring the cobas I 602, MASS SPEC  very early on to Saudi Arabia and the UAE, which are two of our key investment countries in the Middle East.

Collaborating with visionary institutions like King Faisal Specialist Hospital allows us to put our latest clinical advancements directly into the hands of experts who are ready to utilize them and are serious in their own ambition.

For us, this isn’t just about expanding our footprint; it is about investing in partnership with the markets that have the ambition, the infrastructure, and the capability to lead global healthcare trends.

Q3. What changes for laboratories, clinicians and patients when mass spectrometry moves from a specialist capability to a routine one?

To understand the true impact of this shift, it helps to look at the broader landscape of modern healthcare. Today, health systems worldwide are navigating a clear set of challenges: the need to operate with maximum efficiency within resource-constrained environments, the pressure to better support our healthcare professionals, and the necessity of automating labor-intensive, manual processes that add little operational value. At the core of all these challenges is a single goal: providing high-medical-value results that give clinicians the precise decision support they need for critical patient care.

This is exactly where the transition of mass spectrometry from a specialized capability to a routine one becomes a major milestone for the entire health ecosystem. The clinical use cases are some of the highest-value in modern medicine, including therapeutic drug monitoring, endocrinology, Vitamin D, and drugs of abuse testing and metabolic disease, and the Middle East has a disproportionate share of the patient need in those areas.

Historically, mass spectrometry was a highly complex, manual technique confined to niche research centers. By automating and seamlessly integrating this gold-standard technology into standard laboratory workflows, we are directly addressing those macroeconomic needs across three distinct levels:

• For Laboratories: It removes operational complexity and automates manual tasks. This allows labs to optimize their existing workforce, reduce human error, and scale their testing capacity without needing niche, specialized operators.
• For Clinicians: It provides exceptionally precise, high-medical-value data in a fraction of the traditional turnaround time. It functions as a powerful, reliable decision-support tool, allowing physicians to make critical, time-sensitive treatment choices with absolute confidence.
• For Patients: It means faster answers and closer access to a higher standard of precision medicine, ultimately shifting the care paradigm away from delayed reaction and toward early, highly targeted intervention.

At a strategic level, this aligns perfectly with what regional governments are pushing for. It shifts the entire healthcare paradigm away from late-stage reaction and moves it toward early intervention and preventive care. It’s arguably one of the biggest leaps forward for patient outcomes in the region right now.

Q4. How does the mass spec rollout connect to Roche’s wider investment posture in the Middle East?

The rollout of the Cobas I 601 Mass Spec  is a perfect reflection of how Roche brings its global leadership to life in a region we view as a top strategic priority. Our ambition is to double patient access to life-changing diagnostics globally, because our tests only have value if people can access them. We combine our global scale with deep local knowledge, understanding what each community needs and delivering solutions that work in real healthcare settings.

The Middle East has emerged as a pivotal growth region for Roche Diagnostics, propelled by large-scale healthcare transformation programs, landmark investments in medical infrastructure, and clear national strategies that emphasize early detection and preventative healthcare.

At Roche, our guiding philosophy is ‘doing now what patients need next.’ This means our strategy will always be rooted in building trusted, sustainable partnerships that can grow, adapt, and scale alongside the changing needs of each country’s healthcare system. By deeply collaborating with governments, healthcare leaders, and pharma partners, we aim to fundamentally strengthen health systems so they can deliver lasting, equitable access to diagnostics.

To achieve this, we are driving an aggressive innovation agenda. We are coming off an unprecedented wave of innovative product launches in the Middle East, last year we had the highest number of launches in our regional history, which serves as a clear signal of our commitment to advancing healthcare here.

Our investment posture focuses on a powerful dual approach to meet regional health goals:

• Advanced Core Lab & Digital Integration: We are scaling fully integrated solutions across core lab, molecular, and tissue diagnostics. By pairing advanced platforms like the cobas Mass Spec with our digital portfolio, including navify, we are integrating digital tools for better data utilization in laboratories, turning raw outputs into structured, clinically actionable insights.
• Decentralized Near-Patient Care: Simultaneously, a major focus for us is bringing testing closer to the patient. A significant milestone in this effort is the integration of LumiraDx into Roche’s portfolio. This dramatically expands our rapid-testing capabilities across conditions ranging from acute infectious diseases to chronic, non-communicable illnesses, reducing the traditional reliance on central laboratories.

This dual approach means faster, evidence-based clinical decisions that reach more patients, drive immense operational efficiency across healthcare systems, and align perfectly with national healthcare visions.

Deploying this level of sophisticated technology requires a high degree of institutional readiness and continuous support. Because Roche has one of the largest Diagnostics teams in the Middle East, our world-class service and support expertise serve as our ultimate differentiator. We are able to walk step-by-step with visionary partners, such as Prepaire Labs in the UAE, the very first private laboratory in the region to adopt the cobas Mass Spec, while actively planning subsequent rollouts in Jordan, Qatar, and beyond. We are choosing to lead the future of healthcare from inside the region, ensuring Middle Eastern health systems have the sustainable tools they need to thrive.

Q5. Beyond mass spectrometry, Roche has just received CE Mark for a blood test for Alzheimer’s. How does that fit the same regional thesis?

Alzheimer’s disease is one of the most pressing and profound global health challenges of our time. The scale of the problem is truly staggering: an estimated 75% of people living with dementia remain undiagnosed, and those who do eventually get answers typically wait an average of three and a half years after symptoms first appear. This creates a prolonged period of distressing uncertainty for families and puts a massive, unsustainable strain on healthcare systems worldwide.

The introduction of our Elecsys pTau217 blood test allows us to make an immediate, monumental impact on this trajectory. By replacing costly PET scans or invasive spinal fluid assessments – which are notoriously complex and painful procedures for patients – with a simple, highly accurate routine blood draw, we are opening the door to diagnosis at the absolute ‘dawn’ of the disease and more consistent painfree checks. This means clinicians can catch pathology much earlier, when interventions and care planning have the greatest potential to preserve a patient’s independence and quality of life.

This fits our strategic thesis in the Middle East perfectly. Regional health transformations are explicitly built around early detection and preventative care. Because this breakthrough test runs seamlessly on the automated cobas laboratory systems already widely deployed across the region, we can scale this life-changing capability rapidly without requiring health systems to invest in entirely new infrastructure. It allows us to deliver on our commitment to ‘doing now what patients need next,’ helping Middle Eastern health systems eliminate diagnostic bottlenecks and lead the way in proactive neurodegenerative care.

Because the pTau217 assay is engineered to run on the existing cobas integrated platforms already powering over 3,000 laboratories across the region, we will not just be launching a test; we are leveraging, pre-installed diagnostic network. This means the Middle East healthcare system achieves immediate, population-scale access through a simple blood draw, allowing laboratories to manage the transition from research to routine Alzheimer’s screening without needing to rebuild their physical infrastructure. Take a capability that once sat inside a small number of specialist centres, and make it something a health system can rely on at scale.

What matters for this region is where it is landing. And once again, the Middle East is the launchpad, not an afterthought. The UAE is among the very first markets in the world to get this into a clinical research setting, through our partnership with Metabolic – previously GluCare Health in Dubai, focused on people at elevated risk including those living with diabetes and other metabolic conditions.

It completely reinforces our core thesis: we are actively choosing the Middle East for early access because the region has the vision to run with it.

Q6. How are you working with healthcare systems and partners on the transition?

True Healthcare transformation requires true long-term enduring partnership with a shared vision; the future can only be co-created… no one can do it alone. As the Middle East undergoes a monumental shift toward advanced medical infrastructure and preventative care, healthcare leaders recognize that successfully navigating this evolution requires a deep, collaborative alliance rather than just a technology provider.

We have been operating in the Middle East for over 6 decades with local partners enabling better outcomes to patients through both our transformative solutions as well as navigating the end to end patient journey. We continuously build initiatives from capacity building, local talent development, Lab technicians training, to partnering with governments on national transformation agendas.

We closely collaborate with  our partners’ teams to map out clinical use cases, handle intensive training, integrate new workflows, and successfully guide them through the leap from manual to fully automated. We’re applying this partnership approach across the board, whether it’s with partners like NUPCO, HHC, DOH, DHA, Sultan Qaboos University Hospital in Oman, American University of Beirut Medical Center in Lebanon, Prepaire Labs in the UAE, Strategic partners in KSA,  Jordan and Qatar, just to name a few…

At the end of the day, technology is only half the battle, the partnership is the rest.

Q7. Looking ahead, what does the next chapter of clinical diagnostics in this region look like?

The next chapter of clinical diagnostics in the Middle East is defined by a profound transformation in how healthcare is delivered, and Roche is fully committed to support driving the transformation

The next chapter is a total evolution. We are moving away from the traditional, isolated laboratory and building a digital intelligence backbone. We are entering an era of active disease elimination, driven by smart digital ecosystems and population-level screening. By tying AI and high-throughput molecular testing together through platforms like navify, we can actually intercept massive health burdens long before symptoms even surface.

But here’s the real key: all this innovation only matters if it translates into equitable access. We have to ensure these breakthroughs reach everyone equally, supporting earlier detection and building healthcare systems that are genuinely sustainable for the long haul. By combining our strengths, we can deploy a “digital shield” capable of completely eliminating HPV-driven cervical cancer, wiping out tuberculosis transmission, and halting advanced diabetes right in its tracks. For Roche, delivering breakthrough innovation only truly matters if it contributes to building sustainable, resilient healthcare systems that can manage long-term operational strains while offering lasting, equitable access to care. With our deep-rooted history and expanding footprint in the Middle East, we are dedicated to investing in the local workforce and infrastructure.